A PARP suc­ces­sor? Michi­gan aca­d­e­m­ic team touts po­ten­tial of an ag­ing — but still ex­per­i­men­tal — As­traZeneca drug in DNA dam­age re­pair

As­traZeneca has al­ready made bil­lions on their PARP Lyn­parza, work­ing along­side ri­vals like GSK, Pfiz­er and Clo­vis to demon­strate the widen­ing po­ten­tial of a drug that throws a mon­key wrench in the DNA dam­age re­pair process — al­low­ing drugs to kill off can­cer cells. Now a group of in­ves­ti­ga­tors at the Uni­ver­si­ty of Michi­gan have pub­lished new re­search to show how a sim­i­lar ap­proach tar­get­ing Wee1 has the po­ten­tial to do the same for tough-to-treat cas­es of ad­vanced pan­cre­at­ic can­cer.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.